CAS 2062661-53-2

Tovinontrine

CAS: 2062661-53-2

Tovinontrine

Purity: ≥98%

Molecular weight: 394.47g/mol

Ref: 54-BUP01341

Tovinontrine

CAS: 2062661-53-2

Tovinontrine is a potent Chinese anticancer drug that targets the kinase pathway in cancer cells. It has been shown to inhibit cell cycle progression and induce apoptosis in cancer cells, making it a promising candidate for cancer treatment. Tovinontrine also has protein kinase inhibitory activity and can be used as an inhibitor of tumor growth. This drug is highly effective against various types of human cancers, including breast, lung, prostate, and colon cancer. Additionally, Tovinontrine has been shown to have synergistic effects with other anticancer drugs such as betamethasone and vitamin D3. The urine concentration of Tovinontrine can be used as a biomarker for the diagnosis and monitoring of cancer patients undergoing treatment with this drug.

Formula: C₂₁H₂₆N₆O₂

Purity: Min. 95%

Molecular weight: 394.5 g/mol

Ref: 3D-MHD66153

Tovinontrine

CAS: 2062661-53-2

Tovinontrine (IMR-687) (IMR-687) is a potent and selective inhibitor of phosphodiesterase-9 (PDE9), designed to target sickle cell disease treatment.

Formula: C₂₁H₂₆N₆O₂

Purity: 98.14%

Color and Shape: Solid

Molecular weight: 394.47

Ref: TM-T61833